Free Trial
NASDAQ:TERN

Terns Pharmaceuticals (TERN) Stock Price, News & Analysis

Terns Pharmaceuticals logo
$7.01 -0.06 (-0.85%)
As of 10:03 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Terns Pharmaceuticals Stock (NASDAQ:TERN)

Key Stats

Today's Range
$7.02
$7.14
50-Day Range
$3.68
$7.25
52-Week Range
$1.87
$11.40
Volume
40,748 shs
Average Volume
1.16 million shs
Market Capitalization
$613.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.63
Consensus Rating
Moderate Buy

Company Overview

Terns Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

TERN MarketRank™: 

Terns Pharmaceuticals scored higher than 76% of companies evaluated by MarketBeat, and ranked 256th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Terns Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Terns Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Terns Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Terns Pharmaceuticals are expected to decrease in the coming year, from ($1.19) to ($1.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Terns Pharmaceuticals is -6.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Terns Pharmaceuticals is -6.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Terns Pharmaceuticals has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Terns Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.68% of the float of Terns Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Terns Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in Terns Pharmaceuticals has recently increased by 11.79%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Terns Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Terns Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.68% of the float of Terns Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Terns Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in Terns Pharmaceuticals has recently increased by 11.79%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Terns Pharmaceuticals has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Terns Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    Only 5 people have searched for TERN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Terns Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Terns Pharmaceuticals insiders have bought 5,022.87% more of their company's stock than they have sold. Specifically, they have bought $186,575.00 in company stock and sold $3,642.00 in company stock.

  • Percentage Held by Insiders

    Only 1.50% of the stock of Terns Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    98.26% of the stock of Terns Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Terns Pharmaceuticals' insider trading history.
Receive TERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TERN Stock News Headlines

This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
Terns (TERN) Q2 Net Loss Narrows 16%
See More Headlines

TERN Stock Analysis - Frequently Asked Questions

Terns Pharmaceuticals' stock was trading at $5.54 at the beginning of 2025. Since then, TERN stock has increased by 27.6% and is now trading at $7.07.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) posted its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02.

Terns Pharmaceuticals (TERN) raised $101 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO.

Terns Pharmaceuticals' top institutional investors include Candriam S.C.A. (2.71%), Geode Capital Management LLC (1.87%), Adage Capital Partners GP L.L.C. (1.46%) and Franklin Resources Inc. (1.46%). Insiders that own company stock include Orbimed Advisors Llc, Hongbo Lu, Biosciences Fund V LP Lav, Vivo Opportunity, Llc, Mark J Vignola, Emil Kuriakose, Amy L Burroughs, Andrew Gengos, Melita Sun Jung and Jill M Quigley.
View institutional ownership trends
.

Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Terns Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX).

Company Calendar

Last Earnings
8/05/2025
Today
8/28/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TERN
CIK
1831363
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$7.50
Potential Upside/Downside
+121.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.85 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-27.35%
Return on Assets
-26.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
24.70
Quick Ratio
24.70

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.49 per share
Price / Book
2.03

Miscellaneous

Outstanding Shares
87,510,000
Free Float
86,198,000
Market Cap
$618.70 million
Optionable
Not Optionable
Beta
-0.05
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:TERN) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners